Abstract:ABSTRACT Background The previous phase II study of the oral S-1 plus oral Leucovorin (LV) (2 weeks on/2 weeks off) for patients with untreated metastatic colorectal cancer (mCRC) have shown to be effective, but the grade 3 toxic effects (diarrhea, stomatitis, and anorexia) were observed with relatively high frequency. In this phase II study, we modified the administration schedule of S-1 plus LV regimens for well-tolerated toxic effects and evaluated the efficacy. Methods Patients were eligible as follows: histologically confirmed adenocarcinoma, age ≥ 20, ECOG PS 0-1, no prior chemotherapy, at least one measurable lesion by RECIST ver1.0 criteria, adequate organ function, and written informed consent. S-1 (40-60 mg b.i.d.) and LV (25 mg b.i.d.) were orally administered for 1 week, followed by 1 week rest period. Treatment was repeated until the onset of disease progression or unacceptable adverse events occurred. The primary end point was the response rate (RR), and the secondary end points were efficacy and safety. This trial was supported by Taiho Pharmaceutical CO., Ltd. ClinicalTrials.gov Identifier: NCT00891332 Results From October 2008 to June 2009, 73 patients were enrolled in Japan and China. Of the eligible 71 patients, the median age was 60 (range 27-84), male/female was 38/33, PS: 0/1 was 39/32, and Japan/China was 32/39. RR as primary end point was 53.5% (95% CI, 41.3–65.5), and disease control rate was 83.1%. With a median follow-up period of 26.4 months, the median progression-free survival was 6.5 months. Median overall survival was 24.3 months with the survival rate of 77.5% at 1 year and 53.2% at 2 years. The incidences of grade 3 adverse drug reactions were diarrhea 8.3%, stomatitis 8.3%, anorexia 2.8%, neutropenia 9.7%, and there was no treatment-related death. Conclusions The modified treatment schedule of S-1 plus LV (1w on/ 1w off) showed similar good efficacy and better tolerability compared with the previous treatment schedule (2w on/ 2w off). This therapy showed promising activity in patients with untreated mCRC without the concurrent use of irinotecan, oxaliplatin, or molecular-targeted drugs.

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.

A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer

Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin

[Phase II Clinical Trial of Oxaliplatin Alone for Refractory Advanced Colorectal Cancer].

A Phase II Study of Biweekly Oxaliplatin Plus S-1 Combination Chemotherapy As a First-Line Treatment for Patients with Metastatic or Advanced Gastric Cancer in China

[Multicenter Phase II Study of Modified FOLFIRI Regimen in the Advanced Colorectal Cancer Patient Refractory to Fluoropyrimidine and Oxaliplatin].

Phase I Dose-Escalating Study of S-1 in Combination with Oxaliplatin for Patients with Advanced And/or Metastatic Colorectal Cancer

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer

Shenlingcao Oral Liquid for Patients with Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy after Radical Resection: A Multicenter Randomized Controlled Trial

Phase II Study of S-1 Plus Leucovorin (1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China: Comparing Results of Each Country and Updating Overall Survival

Safety and Tolerability Profile of Raltitrexed in Chinese Patients with Locally Advanced or Recurrent and Metastatic Colorectal Cancer: A Phase IV Trial.

Phase II Study of S-1 Plus Leucovorin (a New 1-Week Treatment Regimen Followed by a 1-Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China.

A multicenter randomized phase Ⅱ trial of oxaliplatin in patients with advanced colorectal cancer

Phase II Study of S-1 Plus Leucovorin (New 1 Week Treatment Regimen Followed by 1 Week Rest Period) in Patients with Untreated Metastatic Colorectal Cancer in Japan and China

Clinical Observation of Treatment for Advanced Colorectal Cancer with S-1 Plus Oxaliplatin

A Phase II Trial of Oxaliplatin Plus S-1 As a First-Line Chemotherapy for Patients with Advanced Gastric Cancer

Olaparib Maintenance Monotherapy in Chinese Patients with Platinum‐sensitive Relapsed Ovarian Cancer: China Cohort from the Phase III SOLO2 Trial

Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study

A meta-analysis of the efficacy and safety of S-1 combined with oxaliplatin for metastatic colorectal cancer

S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.